Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol

Pavkov, Richard; Müeller, Stefan; Fiebich, Katrin; Singh, Dilraj; Stowasser, Frank; Pignatelli, Giovanni; Walter, Benoît; Ziegler, Dominik; Dalvi, Mukul; Dederichs, Juergen; Rietveld, Ilse

doi:10.1185/03007995.2010.518916

Cited by 86 publications

(89 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This concept has been elaborated into the PowderHale ® technology by the University of Bath and Vectura, using magnesium stearate or leucine as additives, later referred to as Force Control Agents (FCAs). The technology, based on a dry mechanical fusion (mechanofusion) process [82,83], is licensed by Vectura to GlaxoSmithKline (for the formulations in the Ellipta ® ) [84] and Novartis (for the Breezhaler ® ) [85]. Also the Chiesi powder formulation for beclomethasone dipropionate and formoterol fumarate (Foster, or Fostair), administered with the NEXThaler ® device, contains magnesium stearate.…”

Section: 'Repair Actions' For Design Weaknesses Of Early Dpi Conceptsmentioning

confidence: 99%

Dry powder inhalation: past, present and future

Boer

Hagedoorn

Hoppentocht

et al. 2016

Expert Opinion on Drug Delivery

221

View full text Add to dashboard Cite

Introduction: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers. Areas covered: The consequences of the choices made for early DPI development with respect of efficacy, production costs and safety and the tremendous amount of energy put into understanding and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed particle manufacturing and powder formulation processes are presented as well as the challenges, objectives, and new tools available for future DPI design. Expert opinion: Improved inhaler design is desired to make DPIs for future applications cost-effective and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and designing simple and self-intuitive inhalers, which give good feedback to the patient about the inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations, disposable inhalers may be preferred. ARTICLE HISTORY

show abstract

Section: 'Repair Actions' For Design Weaknesses Of Early Dpi Conceptsmentioning

confidence: 99%

Dry powder inhalation: past, present and future

Boer

Hagedoorn

Hoppentocht

et al. 2016

Expert Opinion on Drug Delivery

221

View full text Add to dashboard Cite

show abstract

“…In general, very young and elderly patients, and those experiencing a severe exacerbation may not be able to generate sufficient inhalation flow to generate particles capable of reaching the lungs. In a paper by Pavkov the peak inspiratory flow through Breezhaler was evaluated in 26 moderate to severe COPD patients, who were able to generate a flow greater than 60 L/min [21]. Very few data are available regarding lung deposition: it was estimated that about 34% of the labelled dose of indacaterol could be delivered through Breezhaler [22].…”

Section: Comparing Devices For Chronic Obstructive Pulmonary Diseasesmentioning

confidence: 99%

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

Scichilone

Benfante

Bocchino

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

a b s t r a c tInhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should be shared also by clinicians. Clinicians have access to a wide selection of pressurised metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) that can be used effectively when matched to the needs of individual patients; this should be perceived as an opportunity rather than a limitation.

show abstract

“…Consequently, it is suitable for use by patients with a wide range of COPD severities, delivering a consistent dose irrespective of disease severity and age [59].…”

Section: Indacaterol/ Glycopyrronium: Choosing the Right Devicementioning

confidence: 99%